Press release from the Competition Council regarding the economic concentration project concerning the acquisition of exclusive control of the company “Opella Healthcare SAS” by the company “Clayton, Dubilier & Rice Fund XII, LP” through the acquisition of approximately 50% of its capital and associated voting rights.

In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the “operation summary” below, containing the information provided by the parties.

This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.

The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.

Names of the companies and groups concerned:

• The acquirer: “Clayton, Dubilier & Rice Fund XII, LP”;
• The target: “Opella Healthcare SAS”;

Nature of the operation

• Acquisition of exclusive control.

Economic sectors concerned

• Pharmaceuticals and dietary supplements sector.

Deadline for interested third parties to submit their observations

• 10 days from the date of publication of this press release, i.e. December 26, 2024.

NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES

The Competition Council has received notification of an economic concentration operation concerning the acquisition of exclusive control of the company “Opella Healthcare SAS” by the company “Clayton, Dubilier & Rice Fund XII, LP” through the acquisition of approximately 50% of its capital and associated voting rights.

“Clayton, Dubilier & Rice Fund XII, LP” is a private equity fund registered in the Cayman Islands and controlled by “Clayton, Dubilier & Rice”, a private investment group based in the United States. The group’s strategy is to acquire and manage stakes in companies across various sectors, including industry, business services, financial services, distribution, healthcare, and technology.

“Opella Healthcare SAS” is a French simplified joint-stock company. The company is a subsidiary of the Sanofi group and is primarily active globally in the research, development, manufacturing, and marketing of over-the-counter pharmaceutical products, vitamins, minerals, dietary supplements, cosmetics, and other personal care products.

 

Done in Rabat on December 12, 2024